5 Best Long Term US Stocks to Buy Right Now

4. Boston Scientific Corporation (NASDAQ:BSX)

Number of Hedge Fund Holders: 110

5-Year Average Revenue Growth: 13.52%

On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model after Boston Scientific re-entered the TAVR market through its stake in MiRus. Baird said the move is expected to provide modest accretion.

On May 18, BofA lowered its price goal on BSX to $68 from $105 and kept a Buy rating on the stock. The change followed meetings with 34 medtech companies in Las Vegas last week. The analyst said the firm updated several price targets to reflect what it called “the new reality of medtech valuations” amid a slower product cycle environment, concerns around the ACA and healthcare utilization, rising inflation after the war, and investor focus shifting toward “data centers over healthcare.”

Also on May 18, Boston Scientific announced a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank as part of its existing $5 billion buyback program. The company said it will initially receive around 30.4 million shares based on the May 15, 2026, closing stock price of $52.68. The final number of shares will depend on the stock’s average trading price during the term of the agreement.

Boston Scientific expects the ASR program to be completed by June 30, 2026. After the transaction, the company will still have $3 billion remaining under its share repurchase authorization. Management also said the buyback is expected to contribute about $0.02 to adjusted earnings per share for full-year 2026.

Boston Scientific Corporation (NASDAQ:BSX) develops, manufactures, and markets medical devices used across a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology, and Neuromodulation.